Details of Disease

General Information of Disease (ID: DISBZRMJ)

Disease Name	Uterine fibroids
Synonyms	leiomyoma, uterine; UL; uterine leiomyoma; uterus fibroma; uterine body leiomyoma; leiomyoma of the corpus uteri; leiomyoma of body of uterus; uterine fibroid; fibroid of the uterine body; leiomyoma of the uterine body; uterine corpus leiomyoma; leiomyoma of the uterine corpus; uterine corpus fibroid; fibroid of uterine corpus; fibroid of body of uterus; leiomyoma of uterine body; corpus uteri leiomyoma; uterine corpus leiomyomata; fibroid of the corpus uteri; body of uterus leiomyoma; uterine body fibroid; corpus uteri fibroid; fibroid of uterine body; fibroid of corpus uteri; leiomyoma of uterine corpus; fibroid of the uterine corpus; plexiform leiomyoma; leiomyoma of corpus uteri; body of uterus fibroid; fibroid of the body of uterus; leiomyoma of the body of uterus
Disease Class	2E86: Uterine fibroid
Definition	A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.
Disease Hierarchy	DIS405IH: Benign neoplasm of corpus uteri DISH5078: Fibroma DIS8I9FS: Hereditary disorder of connective tissue DISLDDFN: Leiomyoma DISBZRMJ: Uterine fibroids
ICD Code	ICD-11 ICD-11: 2E86.0 Expand ICD-11 '2E86.0 Expand ICD-10 'D25; 'D25.0; 'D25.1; 'D25.2; 'D25.9
Disease Identifiers	MONDO ID MONDO_0007886 MESH ID D007889 UMLS CUI C0042133 OMIM ID 150699 MedGen ID 21801 HPO ID HP:0000131 SNOMED CT ID 1.47E+14

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Elagolix	DMB2C0E	Phase 3	Small molecular drug	[1]
S-PRAnt	DMFAO5G	Phase 2	NA	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TAK-013	DM0TDZI	Discontinued in Phase 2	Small molecular drug	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
COL-1777	DMQ50I7	Investigative	NA	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 54 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HMGA2	TTSTVM0	No Known	Unknown	[5]
CR2	TT0HUN7	Limited	Biomarker	[6]
DFFA	TTYVQ9C	Limited	Biomarker	[7]
DFFB	TT2SRE0	Limited	Biomarker	[7]
GNRH1	TT0ID4A	Limited	Biomarker	[8]
GPER1	TTDSB34	Limited	Biomarker	[9]
HCAR2	TTWNV8U	Limited	Altered Expression	[10]
MYLK	TT18ETS	Limited	Altered Expression	[11]
PDGFRB	TTI7421	Limited	Genetic Variation	[12]
NACC1	TT4AQ5F	moderate	Altered Expression	[13]
ADAMTS4	TTYG6BU	Strong	Biomarker	[14]
AMHR2	TTZDCPK	Strong	Genetic Variation	[15]
ATG7	TTLVB9Z	Strong	Biomarker	[16]
CCN1	TTPK79J	Strong	Biomarker	[17]
CD6	TTMF6KC	Strong	Genetic Variation	[18]
CDK19	TTNABU9	Strong	Genetic Variation	[19]
CDK8	TTBJR4L	Strong	Biomarker	[19]
CPN1	TT8V2KD	Strong	Biomarker	[20]
EBI3	TTJF68X	Strong	Biomarker	[21]
FGR	TTPOGS1	Strong	Altered Expression	[22]
FOXO1	TTLRVIA	Strong	Genetic Variation	[23]
GJC1	TTEP7OC	Strong	Biomarker	[24]
GNRHR	TT8R70G	Strong	Biomarker	[25]
GRIA2	TTWM461	Strong	Altered Expression	[26]
GRM2	TTXJ47W	Strong	Altered Expression	[26]
HDAC8	TTT6LFV	Strong	Genetic Variation	[27]
HMGA1	TTBA219	Strong	Altered Expression	[28]
HOXA11	TTEX4ZA	Strong	Biomarker	[29]
HOXA13	TTN26OM	Strong	Biomarker	[30]
HSD17B1	TTIWB6L	Strong	Genetic Variation	[31]
HSD17B2	TT0PT1R	Strong	Genetic Variation	[32]
ITGAV	TTT1R2L	Strong	Altered Expression	[33]
ITPR1	TT5HWAT	Strong	Genetic Variation	[34]
KAT6B	TTH4VJL	Strong	Genetic Variation	[35]
MSTN	TTM8I2X	Strong	Altered Expression	[36]
MUC16	TTC1PS3	Strong	Genetic Variation	[37]
NLRC5	TTWZC78	Strong	Altered Expression	[38]
OXTR	TTSCIUP	Strong	Biomarker	[39]
PRLR	TTBPXMA	Strong	Biomarker	[40]
RIC8A	TTDFTJG	Strong	Genetic Variation	[23]
RTN4	TT7GXMU	Strong	Genetic Variation	[41]
RXFP1	TTMAHD1	Strong	Altered Expression	[42]
SIRT3	TTVZLIJ	Strong	Genetic Variation	[23]
SLC27A4	TT20AYF	Strong	Altered Expression	[20]
SMAD3	TTHQZV7	Strong	Biomarker	[43]
SMN1	TT8QL6X	Strong	Biomarker	[44]
SORD	TTLSRBZ	Strong	Genetic Variation	[45]
TACR2	TTYO0A3	Strong	Altered Expression	[46]
TACR3	TTBPGLU	Strong	Biomarker	[47]
TKTL1	TTNQ1J3	Strong	Altered Expression	[48]
TNFSF13	TTOI1RM	Strong	Genetic Variation	[34]
TRIM27	TTTO3QN	Strong	Altered Expression	[49]
WNT7A	TT8NARC	Strong	Altered Expression	[50]
INHBA	TTVB30D	Definitive	Biomarker	[43]
------------------------------------------------------------------------------------


⏷ Show the Full List of 54 DTT(s)

This Disease Is Related to 5 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC27A1	DTKDTML	Strong	Altered Expression	[20]
SLC27A6	DTG4CWJ	Strong	Altered Expression	[20]
SLC5A3	DT8ACN1	Strong	Altered Expression	[51]
SLC7A3	DTXQR1W	Strong	Genetic Variation	[23]
SLC7A8	DTJF3DX	Strong	Biomarker	[52]
------------------------------------------------------------------------------------

This Disease Is Related to 6 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CHST3	DEQIZP2	Strong	Altered Expression	[53]
CYP4F3	DEFCMPI	Strong	Biomarker	[54]
DHCR7	DEL7GFA	Strong	Genetic Variation	[55]
HSD17B7	DEDMWFX	Strong	Altered Expression	[53]
SULT1B1	DED5UR3	Strong	Genetic Variation	[23]
UGT1A8	DE2GB8N	Strong	Biomarker	[56]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DME(s)

This Disease Is Related to 139 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
HMGA2	OTBMBHHL	No Known	Unknown	[5]
ADCY10	OTYSTB0R	Limited	Altered Expression	[10]
DLEC1	OTMKKBUW	Limited	Altered Expression	[57]
FERMT2	OTZNPWWX	Limited	Altered Expression	[58]
FERMT3	OTFQOT3C	Limited	Altered Expression	[58]
FMOD	OT9EJ5H8	Limited	Biomarker	[59]
HOXA10	OTB6GQ09	Limited	Altered Expression	[29]
IFI27	OTI2XGIT	Limited	Biomarker	[60]
IFITM1	OTECO1G8	Limited	Biomarker	[61]
KANSL1	OTYNSNNZ	Limited	Biomarker	[35]
MAGEC3	OT0KDWZN	Limited	Altered Expression	[10]
PCP4	OTM1XXYX	Limited	Biomarker	[62]
POTEM	OT7L2HGH	Limited	Biomarker	[63]
RAD51B	OTCJVRMY	Limited	Altered Expression	[64]
RFTN1	OT8875JE	Limited	Altered Expression	[58]
SMTN	OT4R2TYK	Limited	Biomarker	[65]
SPINT1	OT1CLR5L	Limited	Altered Expression	[66]
TES	OTL8PP6V	Limited	Altered Expression	[67]
RAD50	OTYMU9G1	Disputed	Altered Expression	[68]
ACTRT3	OT2U08K8	Strong	Genetic Variation	[23]
ADAMTS15	OTYB6JS3	Strong	Altered Expression	[14]
ADGRV1	OTLVXHHP	Strong	Biomarker	[69]
AKAP13	OTOZAR14	Strong	Biomarker	[70]
ARNT	OTMSIEZY	Strong	Altered Expression	[71]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[72]
BABAM2	OTOY7FNT	Strong	Genetic Variation	[23]
BET1	OTGX2557	Strong	Genetic Variation	[73]
BET1L	OT5QVYBZ	Strong	Genetic Variation	[74]
BMP8B	OTJC3AB9	Strong	Genetic Variation	[75]
C11orf65	OTKOIR0G	Strong	Genetic Variation	[23]
CALD1	OTNJKJ6Q	Strong	Biomarker	[76]
CCN5	OTADU8JJ	Strong	Altered Expression	[77]
CCNB1IP1	OTOTVMC8	Strong	Genetic Variation	[78]
CCNC	OTMVK4K4	Strong	Genetic Variation	[19]
CCNG1	OT17IA9L	Strong	Biomarker	[79]
CDC42	OT5QBC5M	Strong	Genetic Variation	[74]
CKS2	OTPTMHIV	Strong	Biomarker	[80]
COG5	OTZEG7K0	Strong	Biomarker	[81]
COG6	OTDLQITC	Strong	Genetic Variation	[23]
COL4A2	OTJK1LKN	Strong	Altered Expression	[82]
COL4A5	OTHG60RE	Strong	Genetic Variation	[83]
COL4A6	OTUREU5Z	Strong	Genetic Variation	[83]
COX6C	OT3V7JE5	Strong	Biomarker	[84]
CPN2	OTYOYP14	Strong	Biomarker	[20]
CSMD1	OTIVDSC4	Strong	Genetic Variation	[85]
CUX1	OTU1LCNJ	Strong	Biomarker	[86]
DBI	OT884QY9	Strong	Biomarker	[20]
DCTN6	OTI8PIN9	Strong	Biomarker	[60]
DEPDC5	OTE70JLY	Strong	Genetic Variation	[87]
DNAH2	OT7J5LDI	Strong	Genetic Variation	[34]
DNAJB7	OT4BOECZ	Strong	Biomarker	[88]
DNM3	OTDMUGCR	Strong	Genetic Variation	[74]
DPT	OTINRFC7	Strong	Biomarker	[89]
DST	OTHZBM4X	Strong	Biomarker	[90]
EBAG9	OTTQLQCP	Strong	Altered Expression	[91]
ECM1	OT1K65VW	Strong	Altered Expression	[92]
EDEM2	OTQXYD65	Strong	Biomarker	[93]
EDIL3	OTDVVNS0	Strong	Genetic Variation	[94]
EFNA4	OTITKZQH	Strong	Biomarker	[95]
EGR2	OTAVQ78J	Strong	Altered Expression	[96]
FAM9A	OTBKCFQT	Strong	Posttranslational Modification	[27]
FZD2	OT952ML1	Strong	Altered Expression	[97]
GNRH2	OTORRM53	Strong	Altered Expression	[98]
GREB1	OTU6ZA26	Strong	Genetic Variation	[23]
HK3	OTZKONGB	Strong	Genetic Variation	[34]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[99]
IL4I1	OTK54C63	Strong	Genetic Variation	[100]
KANK1	OT2E7A6W	Strong	Genetic Variation	[23]
KLF11	OTKVQDJD	Strong	Genetic Variation	[101]
LAMB1	OT6J9LJR	Strong	Altered Expression	[102]
LAT2	OTWJDKIH	Strong	Biomarker	[103]
LNX1	OTZWFMAZ	Strong	Genetic Variation	[23]
LTBP1	OTR7Q75L	Strong	Altered Expression	[104]
LTBP2	OTS88GSD	Strong	Biomarker	[105]
MAP2	OT6UYT3X	Strong	Altered Expression	[106]
MBD6	OTDHBSFS	Strong	Altered Expression	[107]
MCM8	OTC93H3S	Strong	Genetic Variation	[23]
MED8	OTSIZ1I7	Strong	Genetic Variation	[108]
MEST	OT8Q4U8Y	Strong	Altered Expression	[109]
MMRN1	OT7ZNYHT	Strong	Biomarker	[110]
MRTFA	OTCVXASM	Strong	Genetic Variation	[34]
MYOCD	OTSJNHTH	Strong	Biomarker	[111]
NCOA1	OTLIUJQD	Strong	Altered Expression	[22]
NCOA2	OTMQFPBB	Strong	Altered Expression	[22]
NCOR1	OT04XNOU	Strong	Altered Expression	[42]
NCOR2	OTY917X0	Strong	Altered Expression	[42]
NEK10	OTN0JAYL	Strong	Genetic Variation	[34]
NEUROG1	OTMJZP9G	Strong	Biomarker	[112]
NFAT5	OTKIE59S	Strong	Altered Expression	[51]
NIPAL1	OTRYI60X	Strong	Genetic Variation	[34]
NLGN2	OTHDYL3H	Strong	Genetic Variation	[34]
NR2F2	OTJFS67N	Strong	Altered Expression	[113]
ORC5	OTFPW8DE	Strong	Biomarker	[114]
OSCP1	OTZ4IFGJ	Strong	Altered Expression	[115]
PACC1	OTKBS8CC	Strong	Genetic Variation	[116]
PBX3	OT8WMVM4	Strong	Genetic Variation	[117]
PCDH11X	OTLICG18	Strong	Genetic Variation	[27]
PCOLCE	OTJXOAN4	Strong	Biomarker	[118]
PDCD6	OT2YA5M8	Strong	Genetic Variation	[119]
PDLIM5	OTLQVV22	Strong	Genetic Variation	[23]
PLAG1	OTT9AJQY	Strong	Altered Expression	[117]
PLD5	OTEVPYNY	Strong	Altered Expression	[120]
PLIN2	OTRXJ9UN	Strong	Biomarker	[121]
PLP1	OT8CM9CX	Strong	Altered Expression	[122]
POGLUT3	OTBTJI73	Strong	Genetic Variation	[23]
PPIG	OTZ8BTTM	Strong	Altered Expression	[123]
PPP4C	OT4B0TNV	Strong	Altered Expression	[124]
PRLHR	OT1THGOP	Strong	Altered Expression	[125]
PTPRR	OT790UA2	Strong	Genetic Variation	[23]
PTTG1	OTIMYS4W	Strong	Biomarker	[126]
RBP1	OTRP1MFC	Strong	Altered Expression	[123]
RGS7	OTDQA90X	Strong	Genetic Variation	[120]
RXFP2	OT7SAT9U	Strong	Altered Expression	[42]
SALL1	OTYYZGLH	Strong	Altered Expression	[127]
SCFD2	OTYM55ET	Strong	Genetic Variation	[34]
SDHB	OTRE1M1T	Strong	Genetic Variation	[45]
SEC62	OTCWEL5F	Strong	Altered Expression	[101]
SFRP1	OT0U9G41	Strong	Altered Expression	[128]
SLAIN2	OTSM5QIO	Strong	Genetic Variation	[34]
SLC66A3	OT8IEN62	Strong	Genetic Variation	[23]
SMN2	OT54RLO1	Strong	Biomarker	[44]
SNIP1	OTL3RA91	Strong	Genetic Variation	[129]
SNRPN	OTQB1ID1	Strong	Genetic Variation	[130]
SPIN1	OT69VAOX	Strong	Biomarker	[131]
SRF	OTW18FQN	Strong	Genetic Variation	[132]
STN1	OT8UWRA3	Strong	Genetic Variation	[23]
SYNE1	OTSBSLUH	Strong	Genetic Variation	[23]
TAC3	OTOJGM38	Strong	Altered Expression	[47]
TAC4	OTYWPPM3	Strong	Biomarker	[46]
TBATA	OTGDMAAL	Strong	Genetic Variation	[133]
TBPL2	OTDEC1KO	Strong	Biomarker	[134]
TET3	OT76U3YF	Strong	Altered Expression	[135]
TFAP2C	OTUDIW05	Strong	Altered Expression	[136]
TNRC6B	OTGVT0SH	Strong	Genetic Variation	[23]
TRADD	OTBOSJHO	Strong	Biomarker	[137]
TSC2	OT47LWI9	Strong	Biomarker	[138]
TSC22D3	OT03UM03	Strong	Biomarker	[139]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[41]
TSPYL2	OTGGW2EF	Strong	Biomarker	[140]
------------------------------------------------------------------------------------


⏷ Show the Full List of 139 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8362).
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033040)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1185).
4	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5	Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet. 2009 Apr;125(3):257-63. doi: 10.1007/s00439-008-0621-6. Epub 2009 Jan 9.
6	Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS.N Engl J Med. 1995 Jan 5;332(1):12-8. doi: 10.1056/NEJM199501053320103.
7	DNA fragmentation factors 40 and 45 (DFF40/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival.Onco Targets Ther. 2017 Sep 14;10:4579-4589. doi: 10.2147/OTT.S142979. eCollection 2017.
8	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.Endocr Relat Cancer. 2012 Jul 22;19(4):541-56. doi: 10.1530/ERC-12-0007. Print 2012 Aug.
9	Bisphenol A promotes the proliferation of leiomyoma cells by GPR30-EGFR signaling pathway.J Obstet Gynaecol Res. 2019 Jul;45(7):1277-1285. doi: 10.1111/jog.13972. Epub 2019 Apr 23.
10	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.
11	Myosin regulatory light chain phosphorylation is associated with leiomyosarcoma development.Biomed Pharmacother. 2017 Aug;92:810-818. doi: 10.1016/j.biopha.2017.05.139. Epub 2017 Jun 10.
12	Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis.JAMA Dermatol. 2019 Aug 1;155(8):946-950. doi: 10.1001/jamadermatol.2019.0114.
13	NAC1, a BTB/POZ protein overexpressed in uterine sarcomas.Anticancer Res. 2012 Sep;32(9):3841-5.
14	Versican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma.J Clin Endocrinol Metab. 2017 May 1;102(5):1631-1641. doi: 10.1210/jc.2016-3527.
15	Sertoli Cell Tumour and Uterine Leiomyoma in Miniature Schnauzer Dogs with Persistent Mllerian Duct Syndrome Caused by Mutation in the AMHR2 Gene.J Comp Pathol. 2018 May;161:20-24. doi: 10.1016/j.jcpa.2018.04.004. Epub 2018 Jun 1.
16	Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an invitro study.Fertil Steril. 2019 Dec;112(6):1150-1159. doi: 10.1016/j.fertnstert.2019.08.007.
17	Novel treatment avenues for uterine leiomyoma: a new implication for endothelin?.Clin Sci (Lond). 2018 Oct 29;132(20):2261-2267. doi: 10.1042/CS20180474. Print 2018 Oct 31.
18	Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity.Hum Mol Genet. 2012 May 15;21(10):2312-29. doi: 10.1093/hmg/dds051. Epub 2012 Feb 17.
19	Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.J Biol Chem. 2018 Mar 30;293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.
20	Expression of the energy substrate transporters in uterine fibroids.Prostaglandins Other Lipid Mediat. 2016 Mar;123:9-15. doi: 10.1016/j.prostaglandins.2016.02.002. Epub 2016 Feb 27.
21	RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth.J Clin Endocrinol Metab. 2018 May 1;103(5):1842-1849. doi: 10.1210/jc.2017-01585.
22	Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells.Cancer Res. 2010 Feb 15;70(4):1722-30. doi: 10.1158/0008-5472.CAN-09-2612. Epub 2010 Feb 2.
23	Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis.Nat Commun. 2019 Oct 24;10(1):4857. doi: 10.1038/s41467-019-12536-4.
24	Expression of the gap junction connexins Cx43, Cx45 and Cx26 in human uterine leiomyomata.Gynecol Endocrinol. 2001 Apr;15(2):113-22. doi: 10.1080/gye.15.2.113.122.
25	Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.Clin Pharmacokinet. 2018 Oct;57(10):1295-1306. doi: 10.1007/s40262-018-0629-6.
26	New potential regulators of uterine leiomyomata from DNA arrays: the ionotropic glutamate receptor GluR2.Biochem Biophys Res Commun. 2003 Dec 5;312(1):249-54. doi: 10.1016/j.bbrc.2003.09.189.
27	Disease-dependent differently methylated regions (D-DMRs) of DNA are enriched on the X chromosome in uterine leiomyoma.J Reprod Dev. 2011 Oct;57(5):604-12. doi: 10.1262/jrd.11-035a. Epub 2011 Jun 17.
28	6p21 rearrangements in uterine leiomyomas targeting HMGA1.Cancer Genet Cytogenet. 2010 Dec;203(2):247-52. doi: 10.1016/j.cancergencyto.2010.08.005.
29	Endometrial Expression of Homeobox Genes and Cell Adhesion Molecules in Infertile Women With Intramural Fibroids During Window of Implantation.Reprod Sci. 2017 Mar;24(3):435-444. doi: 10.1177/1933719116657196. Epub 2016 Jul 19.
30	Identification of the molecular relationship between intravenous leiomyomatosis and uterine myoma using RNA sequencing.Sci Rep. 2019 Feb 5;9(1):1442. doi: 10.1038/s41598-018-37452-3.
31	Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6012-8. eCollection 2015.
32	Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women.Arch Gynecol Obstet. 2012 Sep;286(3):701-5. doi: 10.1007/s00404-012-2328-0. Epub 2012 May 1.
33	Expression of Endometrial Receptivity Genes Increase After Myomectomy of Intramural Leiomyomas not Distorting the Endometrial Cavity.Reprod Sci. 2016 Jan;23(1):31-41. doi: 10.1177/1933719115612929. Epub 2015 Oct 27.
34	Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits.Nat Commun. 2018 Sep 7;9(1):3636. doi: 10.1038/s41467-018-05428-6.
35	Leiomyoma with KAT6B-KANSL1 fusion: case report of a rapidly enlarging uterine mass in a postmenopausal woman.Diagn Pathol. 2019 Apr 25;14(1):32. doi: 10.1186/s13000-019-0809-1.
36	Expression Levels of Myostatin and Matrix Metalloproteinase 14 mRNAs in Uterine Leiomyoma are Correlated With Dysmenorrhea.Reprod Sci. 2015 Dec;22(12):1597-602. doi: 10.1177/1933719115592710. Epub 2015 Jul 1.
37	Predicting Circulating CA125 Levels among Healthy Premenopausal Women.Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1076-1085. doi: 10.1158/1055-9965.EPI-18-1120. Epub 2019 Apr 4.
38	NLRC5 and autophagy combined as possible predictors in patients with endometriosis.Fertil Steril. 2018 Oct;110(5):949-956. doi: 10.1016/j.fertnstert.2018.06.028.
39	Oxytocin receptor and its messenger ribonucleic acid in human leiomyoma and myometrium.Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):620-7. doi: 10.1016/s0002-9378(98)70054-7.
40	Growth hormone receptor messenger ribonucleic acid expression in leiomyoma and surrounding myometrium.Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):814-9. doi: 10.1016/0002-9378(95)90346-1.
41	Association of CAA and TATC Insertion/Deletion Genetic Polymorphisms in RTN4 3'-UTR with Hepatocellular Carcinoma Risk.Pathol Oncol Res. 2018 Jan;24(1):31-34. doi: 10.1007/s12253-017-0204-8. Epub 2017 Jan 31.
42	Relaxin signaling in uterine fibroids.Ann N Y Acad Sci. 2009 Apr;1160:374-8. doi: 10.1111/j.1749-6632.2008.03803.x.
43	A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
44	Subungual Leiyomyoma Presenting as Erythronychia: Case Report and Review of the Literature.J Drugs Dermatol. 2019 May 1;18(5):465-467.
45	Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.Hum Mol Genet. 2005 Aug 1;14(15):2231-9. doi: 10.1093/hmg/ddi227. Epub 2005 Jun 29.
46	Altered expression of the tachykinins substance P/neurokinin A/hemokinin-1 and their preferred neurokinin 1/neurokinin 2 receptors in uterine leiomyomata.Fertil Steril. 2016 Nov;106(6):1521-1529. doi: 10.1016/j.fertnstert.2016.07.007. Epub 2016 Jul 25.
47	Differentially regulated expression of neurokinin B (NKB)/NK3 receptor system in uterine leiomyomata.Hum Reprod. 2013 Jul;28(7):1799-808. doi: 10.1093/humrep/det128. Epub 2013 May 8.
48	Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1.Int J Oncol. 2010 Aug;37(2):265-71. doi: 10.3892/ijo_00000674.
49	A high-throughput open-array qPCR gene panel to identify housekeeping genes suitable for myometrium and leiomyoma expression analysis.Gynecol Oncol. 2014 Jul;134(1):138-43. doi: 10.1016/j.ygyno.2014.04.012. Epub 2014 Apr 24.
50	Decreased expression of Wnt7a mRNA is inversely associated with the expression of estrogen receptor-alpha in human uterine leiomyoma.J Clin Endocrinol Metab. 2001 Jan;86(1):454-7. doi: 10.1210/jcem.86.1.7276.
51	Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells.Fertil Steril. 2011 Jun;95(7):2383-7. doi: 10.1016/j.fertnstert.2011.03.084. Epub 2011 Apr 15.
52	Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells.J Clin Endocrinol Metab. 2009 Nov;94(11):4533-9. doi: 10.1210/jc.2009-1286. Epub 2009 Oct 6.
53	Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.J Clin Endocrinol Metab. 2004 Nov;89(11):5661-8. doi: 10.1210/jc.2003-032085.
54	The role of MSP I CYP1A1 gene polymorphism in the development of uterine fibroids.Fertil Steril. 2010 Dec;94(7):2783-5. doi: 10.1016/j.fertnstert.2010.05.034. Epub 2010 Jul 1.
55	Polymorphisms in vitamin D-related genes and risk of uterine leiomyomata.Fertil Steril. 2014 Aug;102(2):503-510.e1. doi: 10.1016/j.fertnstert.2014.04.037. Epub 2014 Jun 2.
56	Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma.Clin Transl Oncol. 2018 Aug;20(8):1080-1086. doi: 10.1007/s12094-018-1847-y. Epub 2018 Feb 26.
57	Different methylation levels in the KLF4, ATF3 and DLEC1 genes in the myometrium and in corpus uteri mesenchymal tumours as assessed by MS-HRM.Pathol Res Pract. 2019 Aug;215(8):152465. doi: 10.1016/j.prp.2019.152465. Epub 2019 May 23.
58	Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas.Hum Pathol. 2004 Jan;35(1):55-60. doi: 10.1016/j.humpath.2003.08.019.
59	The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy.Cancer Cell Int. 2019 Jun 10;19:157. doi: 10.1186/s12935-019-0870-6. eCollection 2019.
60	Activation of -Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids.J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1517-35. doi: 10.1210/clinem/dgz227.
61	IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.Int J Gynecol Pathol. 2018 Jul;37(4):372-378. doi: 10.1097/PGP.0000000000000424.
62	PEP-19 overexpression in human uterine leiomyoma.Mol Hum Reprod. 2003 Nov;9(11):709-17. doi: 10.1093/molehr/gag088.
63	Expression Profiling of lncRNAs, miRNAs, and mRNAs and Their Differential Expression in Leiomyoma Using Next-Generation RNA Sequencing.Reprod Sci. 2018 Feb;25(2):246-255. doi: 10.1177/1933719117711265. Epub 2017 Jun 7.
64	Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1315-20. doi: 10.1073/pnas.1518752113. Epub 2016 Jan 19.
65	The Use of Smoothelin and Other Antibodies in the Diagnosis of Uterine and Soft Tissue Smooth Muscle Tumors.Appl Immunohistochem Mol Morphol. 2019 May/Jun;27(5):386-391. doi: 10.1097/PAI.0000000000000619.
66	Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.Int J Oncol. 2010 Sep;37(3):605-14. doi: 10.3892/ijo_00000709.
67	Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.Exp Mol Pathol. 2019 Oct;110:104284. doi: 10.1016/j.yexmp.2019.104284. Epub 2019 Jul 10.
68	Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment.Acta Pharmacol Sin. 2019 Jul;40(7):957-970. doi: 10.1038/s41401-018-0184-6. Epub 2018 Nov 26.
69	Uterine tumors with neuroectodermal differentiation: a series of 17 cases and review of the literature.Am J Surg Pathol. 2008 Feb;32(2):219-28. doi: 10.1097/PAS.0b013e318093e421.
70	A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.J Clin Endocrinol Metab. 2019 Mar 1;104(3):970-980. doi: 10.1210/jc.2018-01216.
71	Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
72	RU486 inhibits expression of lysophosphatidic acid induced glycodelin.Am J Obstet Gynecol. 2005 Apr;192(4):1285-93; discussion 1293-4. doi: 10.1016/j.ajog.2004.12.084.
73	Variants in BET1L and TNRC6B associate with increasing fibroid volume and fibroid type among European Americans.Hum Genet. 2013 Dec;132(12):1361-9. doi: 10.1007/s00439-013-1340-1. Epub 2013 Jul 28.
74	A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids.Front Genet. 2019 Jun 12;10:511. doi: 10.3389/fgene.2019.00511. eCollection 2019.
75	Whole exome sequencing of benign pulmonary metastasizing leiomyoma reveals mutation in the BMP8B gene.BMC Med Genet. 2018 Jan 31;19(1):20. doi: 10.1186/s12881-018-0537-5.
76	Myofibroblastic lesions in the oral cavity: Immunohistochemical and ultrastructural analysis.Oral Dis. 2019 Jan;25(1):174-181. doi: 10.1111/odi.12972. Epub 2018 Nov 8.
77	The growth arrest-specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells.Mol Hum Reprod. 2004 Mar;10(3):181-7. doi: 10.1093/molehr/gah028. Epub 2004 Jan 29.
78	Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma.Jpn J Cancer Res. 2001 Feb;92(2):135-9. doi: 10.1111/j.1349-7006.2001.tb01075.x.
79	Increased expression of cyclin G1 in leiomyoma compared with normal myometrium.Am J Obstet Gynecol. 2003 Mar;188(3):634-9. doi: 10.1067/mob.2003.140.
80	Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.Oncol Lett. 2019 Sep;18(3):2845-2852. doi: 10.3892/ol.2019.10668. Epub 2019 Jul 25.
81	Fusion of HMGA2 to COG5 in uterine leiomyoma.Cancer Genet Cytogenet. 2010 Oct 1;202(1):11-6. doi: 10.1016/j.cancergencyto.2010.06.002.
82	Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.Mol Hum Reprod. 2014 Oct;20(10):1009-15. doi: 10.1093/molehr/gau055. Epub 2014 Jul 11.
83	MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma.Mol Hum Reprod. 2018 Nov 1;24(11):556-563. doi: 10.1093/molehr/gay037.
84	Novel gene fusion of COX6C at 8q22-23 to HMGIC at 12q15 in a uterine leiomyoma.Genes Chromosomes Cancer. 2000 Mar;27(3):303-7. doi: 10.1002/(sici)1098-2264(200003)27:3<303::aid-gcc11>3.0.co;2-3.
85	A multi-stage genome-wide association study of uterine fibroids in African Americans.Hum Genet. 2017 Oct;136(10):1363-1373. doi: 10.1007/s00439-017-1836-1. Epub 2017 Aug 23.
86	Identification of CUX1 as the recurrent chromosomal band 7q22 target gene in human uterine leiomyoma.Genes Chromosomes Cancer. 2013 Jan;52(1):11-23. doi: 10.1002/gcc.22001. Epub 2012 Sep 10.
87	Clonally related uterine leiomyomas are common and display branched tumor evolution.Hum Mol Genet. 2015 Aug 1;24(15):4407-16. doi: 10.1093/hmg/ddv177. Epub 2015 May 10.
88	Crosstalk between tongue carcinoma cells, extracellular vesicles, and immune cells in in vitro and in vivo models.Oncotarget. 2017 May 10;8(36):60123-60134. doi: 10.18632/oncotarget.17768. eCollection 2017 Sep 1.
89	Integrated analysis reveals candidate mRNA and their potential roles in uterine leiomyomas.J Obstet Gynaecol Res. 2017 Jan;43(1):149-156. doi: 10.1111/jog.13172. Epub 2016 Dec 17.
90	Bisphenol A induces human uterine leiomyoma cell proliferation through membrane-associated ER36 via nongenomic signaling pathways. Mol Cell Endocrinol. 2019 Mar 15;484:59-68. doi: 10.1016/j.mce.2019.01.001. Epub 2019 Jan 4.
91	Alterations in RCAS1 serum concentration levels during menstrual cycle in patients with uterine leiomyoma and lack of analogical changes in adenomyosis.Gynecol Obstet Invest. 2009;67(3):195-201. doi: 10.1159/000188045. Epub 2008 Dec 20.
92	Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma.Fertil Steril. 2016 Apr;105(4):1070-5. doi: 10.1016/j.fertnstert.2015.12.004. Epub 2015 Dec 17.
93	Transethnic and race-stratified genome-wide association study of fibroid characteristics in African American and European American women.Fertil Steril. 2018 Sep;110(4):737-745.e34. doi: 10.1016/j.fertnstert.2018.04.035.
94	Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features.Genes Chromosomes Cancer. 2006 Mar;45(3):304-12. doi: 10.1002/gcc.20291.
95	Expression profiling of protein tyrosine kinases and their ligand activators in leiomyoma uteri.Syst Biol Reprod Med. 2010 Aug;56(4):318-26. doi: 10.3109/19396361003646109.
96	Early growth response-2 expression in uterine leiomyoma cells: regulation and function.Fertil Steril. 2011 Aug;96(2):439-44. doi: 10.1016/j.fertnstert.2011.05.062. Epub 2011 Jun 24.
97	Strategy for elucidating differentially expressed genes in leiomyomata identified by microarray technology.Fertil Steril. 2003 Aug;80(2):282-90. doi: 10.1016/s0015-0282(03)00953-1.
98	Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor.Fertil Steril. 2007 Jul;88(1):39-46. doi: 10.1016/j.fertnstert.2006.11.098. Epub 2007 Feb 12.
99	Translation and validation of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire for the Brazilian Portuguese language.Sao Paulo Med J. 2017 Mar-Apr;135(2):107-115. doi: 10.1590/1516-3180.2016.0223281016. Epub 2017 Mar 13.
100	Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy?.J Clin Oncol. 2018 Jun 1;36(16):1543-1547. doi: 10.1200/JCO.2017.77.3416. Epub 2018 Apr 18.
101	The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.Reprod Sci. 2016 Feb;23(2):163-75. doi: 10.1177/1933719115584449. Epub 2015 Apr 28.
102	Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22.Oncol Rep. 2005 Mar;13(3):469-72.
103	LAT1 regulates growth of uterine leiomyoma smooth muscle cells.Reprod Sci. 2010 Sep;17(9):791-7. doi: 10.1177/1933719110372419. Epub 2010 Jul 2.
104	Increased expression of latent TGF-beta binding protein-1 and fibrillin-1 in human uterine leiomyomata.Mol Hum Reprod. 2007 May;13(5):343-9. doi: 10.1093/molehr/gam007. Epub 2007 Mar 14.
105	Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium.Mol Hum Reprod. 2002 Mar;8(3):246-54. doi: 10.1093/molehr/8.3.246.
106	Increased expression of neurogenic factors in uterine fibroids.Hum Reprod. 2019 Nov 1;34(11):2153-2162. doi: 10.1093/humrep/dez182.
107	The Expression of MBD6 Is Associated with Tumor Size in Uterine Leiomyomas.Genet Test Mol Biomarkers. 2019 Aug;23(8):523-532. doi: 10.1089/gtmb.2019.0070. Epub 2019 Jul 16.
108	Highly heterogeneous genomic landscape of uterine leiomyomas bywhole exome sequencing and genome-wide arrays.Fertil Steril. 2017 Feb;107(2):457-466.e9. doi: 10.1016/j.fertnstert.2016.10.035. Epub 2016 Nov 23.
109	Imprinting and expression status of isoforms 1 and 2 of PEG1/MEST gene in uterine leiomyoma.Gynecol Obstet Invest. 2010;70(2):120-5. doi: 10.1159/000301555. Epub 2010 Mar 26.
110	Natural Antioxidant Resveratrol Suppresses Uterine Fibroid Cell Growth and Extracellular Matrix Formation In Vitro and In Vivo.Antioxidants (Basel). 2019 Apr 12;8(4):99. doi: 10.3390/antiox8040099.
111	ER inhibited myocardin-induced differentiation in uterine fibroids.Exp Cell Res. 2017 Jan 1;350(1):73-82. doi: 10.1016/j.yexcr.2016.11.007. Epub 2016 Nov 19.
112	Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Biol Reprod. 2017 Sep 1;97(3):337-352. doi: 10.1093/biolre/iox094.
113	Aberrant expression and regulation of NR2F2 and CTNNB1 in uterine fibroids.Reproduction. 2013 Jun 27;146(2):91-102. doi: 10.1530/REP-13-0087. Print 2013 Aug.
114	Physical mapping of distinct 7q22 deletions in uterine leiomyoma and analysis of a recently annotated 7q22 candidate gene.Cancer Genet Cytogenet. 2007 Apr 15;174(2):116-20. doi: 10.1016/j.cancergencyto.2006.11.018.
115	Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids.Mol Endocrinol. 2013 May;27(5):726-40. doi: 10.1210/me.2012-1305. Epub 2013 Apr 2.
116	PAC clone containing the HMGI(Y) gene spans the breakpoint of a 6p21 translocation in a uterine leiomyoma cell line.Genes Chromosomes Cancer. 1996 Nov;17(3):191-3. doi: 10.1002/(SICI)1098-2264(199611)17:3<191::AID-GCC8>3.0.CO;2-#.
117	Genetic heterogeneity in leiomyomas of deep soft tissue.Oncotarget. 2017 Jul 25;8(30):48769-48781. doi: 10.18632/oncotarget.17953.
118	PCOLCE deletion and expression analyses in uterine leiomyomata.Cancer Genet Cytogenet. 2002 Sep;137(2):133-7. doi: 10.1016/s0165-4608(02)00547-2.
119	Variations in the PDCD6 gene are associated with increased uterine leiomyoma risk in the Chinese.Genet Test Mol Biomarkers. 2013 Jul;17(7):524-8. doi: 10.1089/gtmb.2012.0461. Epub 2013 Apr 3.
120	Fine mapping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7-FH interval.Endocr Relat Cancer. 2015 Aug;22(4):633-43. doi: 10.1530/ERC-15-0208. Epub 2015 Jun 25.
121	PLIN2 Functions As a Novel Link Between Progesterone Signaling and Metabolism in Uterine Leiomyoma Cells.J Clin Endocrinol Metab. 2019 Dec 1;104(12):6256-6264. doi: 10.1210/jc.2019-00762.
122	Differential gene expression in uterine leiomyoma.J Lab Clin Med. 2003 May;141(5):297-308. doi: 10.1016/S0022-2143(03)00007-6.
123	Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure.Fertil Steril. 2007 Jun;87(6):1388-98. doi: 10.1016/j.fertnstert.2006.11.093. Epub 2007 Feb 2.
124	G protein-coupled estrogen receptor 1 (GPER 1) mediates estrogen-induced, proliferation of leiomyoma cells.Gynecol Endocrinol. 2015;31(11):894-8. doi: 10.3109/09513590.2015.1092022. Epub 2015 Sep 29.
125	The Epidemiology and Genetics of Uterine Leiomyoma.Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:3-12. doi: 10.1016/j.bpobgyn.2015.11.018. Epub 2015 Dec 2.
126	Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1.Reprod Sci. 2017 Jul;24(7):1005-1013. doi: 10.1177/1933719116675055. Epub 2016 Oct 30.
127	The effect of estrogen and androgen on androgen receptors and mRNA levels in uterine leiomyoma, myometrium and endometrium of human subjects.J Steroid Biochem Mol Biol. 1994 Aug;50(3-4):137-43. doi: 10.1016/0960-0760(94)90020-5.
128	Overexpression of the Wnt5b gene in leiomyoma cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor. J Clin Endocrinol Metab. 2005 Sep;90(9):5349-55. doi: 10.1210/jc.2005-0272. Epub 2005 Jun 21.
129	Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.Anticancer Res. 2010 Jun;30(6):2203-8.
130	Maintenance of imprinting of the insulin-like growth factor II gene (IGF2) and the small nuclear ribonucleoprotein polypeptide N gene (SNRPN) in the human uterus and leiomyoma.Gynecol Obstet Invest. 1996;41(1):50-4. doi: 10.1159/000292036.
131	Romina: A powerful strawberry with in vitro efficacy against uterine leiomyoma cells.J Cell Physiol. 2019 May;234(5):7622-7633. doi: 10.1002/jcp.27524. Epub 2018 Oct 14.
132	Novel SRF-ICA1L Fusions in Cellular Myoid Neoplasms With Potential For Malignant Behavior.Am J Surg Pathol. 2020 Jan;44(1):55-60. doi: 10.1097/PAS.0000000000001336.
133	Spatial differences in biologic activity of large uterine leiomyomata.Fertil Steril. 2006 Jan;85(1):179-87. doi: 10.1016/j.fertnstert.2005.07.1294.
134	Comparative expression of thioredoxin-1 in uterine leiomyomas and myometrium.Mol Hum Reprod. 2014 Feb;20(2):148-54. doi: 10.1093/molehr/gat069. Epub 2013 Oct 15.
135	5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors.J Clin Endocrinol Metab. 2014 Nov;99(11):E2437-45. doi: 10.1210/jc.2014-2264. Epub 2014 Jul 24.
136	7q deletion mapping and expression profiling in uterine fibroids.Oncogene. 2005 Sep 29;24(43):6545-54. doi: 10.1038/sj.onc.1208784.
137	Identification of TRADD as a potential biomarker in human uterine leiomyoma through iTRAQ based proteomic profiling.Mol Cell Probes. 2017 Dec;36:15-20. doi: 10.1016/j.mcp.2017.07.001. Epub 2017 Jul 8.
138	Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.Hum Mol Genet. 2017 Jan 15;26(2):407-419. doi: 10.1093/hmg/ddw397.
139	The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.J Clin Endocrinol Metab. 2020 Mar 1;105(3):716-34. doi: 10.1210/clinem/dgz139.
140	Potential mechanisms of aberrant DNA hypomethylation on the x chromosome in uterine leiomyomas.J Reprod Dev. 2014 Mar 7;60(1):47-54. doi: 10.1262/jrd.2013-095. Epub 2013 Nov 29.